BioCentury | Mar 21, 2018
Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

...four. Patients receive subcutaneous Tremfya at weeks zero and four, and then every eight weeks. Sun Pharma...
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

...least two other companies have inhibitors of ABL proteins in development for PD. In August Sun Pharma Advanced Research Company Ltd....
...Inhibikase Therapeutics Inc., Atlanta, Ga. Neuraly Inc., Baltimore, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sun Pharma Advanced Research Company Ltd....
BioCentury | May 24, 2017
Clinical News

FDA reviewing Sun's psoriasis candidate

...J&J also markets Stelara ustekinumab to treat psoriasis. That drug targets both IL-23 and IL-12. Sun Pharma...
BioCentury | Mar 24, 2017
Company News

EMA reviewing psoriasis candidate from Sun, Almirall

...BLA. J&J's approved psoriasis drug Stelara ustekinumab targets both IL-23 and IL-12 . On Friday, Sun Pharma...
BioCentury | Jan 13, 2017
Company News

Sun Pharma, Novartis deal

...the EU, to treat basal cell carcinoma (BCC). Novartis declined to disclose financial terms, and Sun Pharma...
BioCentury | Oct 3, 2016
Top Story

J&J's guselkumab tops Humira in Phase III psoriasis trial

...Rates for the high dose were 36% at week 12 and 59% at week 28. Sun Pharma...
BioCentury | Aug 8, 2016
Company News

Sun Pharmaceutical, Almirall deal

Sun Pharma granted Almirall rights to develop and commercialize tildrakizumab for psoriasis in Europe. Sun has exclusive, worldwide rights to the compound under a 2014 deal with Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.). Sun...
BioCentury | Jul 25, 2016
Company News

Sun Pharma, Sun Pharmaceutical deal

...Sun Pharma Advanced Research Co. (SPARC) granted Sun Pharma U.S. rights to Elepsia XR levetiracetam, an extended-release...
...September complete response letter citing manufacturing compliance issues. The companies did not respond to inquiries. Sun Pharma Advanced Research Company Ltd....
BioCentury | Apr 11, 2016
Company News

AstraZeneca, Sun Pharmaceutical deal

...AstraZeneca granted Sun Pharma rights to commercialize diabetes drug dapagliflozin in India under the brand name Oxra...
BioCentury | Feb 13, 2016
Company News

Merck, Sun Pharma winding down JV

Indian pharmaceutical company Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said it will wind down operations of its JV with Merck & Co. Inc. (NYSE:MRK) due to "changes in the strategic priorities of both the parent...
Items per page:
1 - 10 of 18
BioCentury | Mar 21, 2018
Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

...four. Patients receive subcutaneous Tremfya at weeks zero and four, and then every eight weeks. Sun Pharma...
BioCentury | Jan 18, 2018
Emerging Company Profile

Computing brain entry

...least two other companies have inhibitors of ABL proteins in development for PD. In August Sun Pharma Advanced Research Company Ltd....
...Inhibikase Therapeutics Inc., Atlanta, Ga. Neuraly Inc., Baltimore, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sun Pharma Advanced Research Company Ltd....
BioCentury | May 24, 2017
Clinical News

FDA reviewing Sun's psoriasis candidate

...J&J also markets Stelara ustekinumab to treat psoriasis. That drug targets both IL-23 and IL-12. Sun Pharma...
BioCentury | Mar 24, 2017
Company News

EMA reviewing psoriasis candidate from Sun, Almirall

...BLA. J&J's approved psoriasis drug Stelara ustekinumab targets both IL-23 and IL-12 . On Friday, Sun Pharma...
BioCentury | Jan 13, 2017
Company News

Sun Pharma, Novartis deal

...the EU, to treat basal cell carcinoma (BCC). Novartis declined to disclose financial terms, and Sun Pharma...
BioCentury | Oct 3, 2016
Top Story

J&J's guselkumab tops Humira in Phase III psoriasis trial

...Rates for the high dose were 36% at week 12 and 59% at week 28. Sun Pharma...
BioCentury | Aug 8, 2016
Company News

Sun Pharmaceutical, Almirall deal

Sun Pharma granted Almirall rights to develop and commercialize tildrakizumab for psoriasis in Europe. Sun has exclusive, worldwide rights to the compound under a 2014 deal with Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.). Sun...
BioCentury | Jul 25, 2016
Company News

Sun Pharma, Sun Pharmaceutical deal

...Sun Pharma Advanced Research Co. (SPARC) granted Sun Pharma U.S. rights to Elepsia XR levetiracetam, an extended-release...
...September complete response letter citing manufacturing compliance issues. The companies did not respond to inquiries. Sun Pharma Advanced Research Company Ltd....
BioCentury | Apr 11, 2016
Company News

AstraZeneca, Sun Pharmaceutical deal

...AstraZeneca granted Sun Pharma rights to commercialize diabetes drug dapagliflozin in India under the brand name Oxra...
BioCentury | Feb 13, 2016
Company News

Merck, Sun Pharma winding down JV

Indian pharmaceutical company Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said it will wind down operations of its JV with Merck & Co. Inc. (NYSE:MRK) due to "changes in the strategic priorities of both the parent...
Items per page:
1 - 10 of 18